Healthspan Education
Book materials, public resources, seminars, and member updates.
Research & Insights
Research coordination, not medical claims.
The Alliance organizes education and participation around longevity research while keeping clear boundaries between public education, physician-led care, research review, and technology infrastructure. Below: how we organize research, the one competition where an Alliance council member is directly competing, and where ATLAS fits as infrastructure.
Research Themes
How the Alliance organizes research.
Participant Journey
Apply, consent, receive updates, attend, engage, and choose next steps.
Verified Delivery
Organized records that show what happened, when, and under what permissions.
Partner Review
Practitioner, foundation, partner, and institutional lanes kept distinct.
The Lionheart Connection
An Alliance council member is competing in the XPRIZE Healthspan.
XPRIZE Healthspan is a seven-year, $101 million global competition launched in 2023, challenging teams to develop therapies that restore muscle, cognitive, and immune function by at least ten years in adults aged 50–80. More than 600 teams from 58 countries entered. In May 2025, the field was narrowed to 100 semifinalists, of whom the Top 40 each received a $250,000 Milestone 1 award to begin early-stage clinical trials.
Among the leadership of the Phenomenal Longevity Alliance is Dr. Howard Leonhardt, whose company Lionheart is part of this field — bringing decades of regenerative-medicine and bioelectric research to the healthspan question.
The milestone ahead. In July 2026, XPRIZE will narrow the field to 10 finalists for a second $10 million milestone prize, with finalist trials running 2026–2029 and a grand prize of up to $81 million awarded in 2030. We will update this page as the field narrows. Standings here reflect the May 2025 Top 40 announcement.
The Broader Field
A diverse and serious field.
The semifinalist field spans biologics, devices, drugs, lifestyle interventions, and personalized monitoring — from university labs and hospital institutes to clinical-stage biotech companies on multiple continents. Approaches range from stem-cell and exosome therapies to mitochondrial-energy compounds, senolytics targeting aging cells, immune-system regeneration, and circadian and dietary protocols.
We follow this field because it represents the credible, evidence-driven end of longevity science — the same standard the Alliance holds itself to. We do not claim affiliation with these teams, and nothing here implies endorsement in either direction.
Where ATLAS Fits
Infrastructure, not therapy.
ATLAS is not a competitor in this field and makes no therapeutic claim. Where ATLAS contributes is the layer beneath any longevity program: participant onboarding, consent-based records, device identity, session telemetry, timestamps, adherence logs, and audit-ready evidence — protected by QuantumVault.
The reason this matters: across the whole field, teams face the same operational hurdle — proving, cleanly and defensibly, what was delivered, to whom, when, and under what permissions. That is the problem ATLAS exists to solve. It changes no clinical result; it makes the record around delivery trustworthy.
ATLAS QuantumVault
- Consent-based participant onboarding
- Device identity and session telemetry
- Timestamps and adherence logs
- Audit-ready evidence organization
- Sensitive-record protection
Sources